Caris & Co Initiates Coverage on ev3 Inc. (EVVV) with a Buy
More News related to EVVV
- Vertos Medical, Inc. Appoints James M. Corbett Chief Executive Officer
- Caris Downgrades ev3 (EVVV) to Above Average
- ev3 (EVVV) Reports Q3 Adj-EPS of $0.04
- ev3 Inc. Reports Third Quarter 2008 Financial Results
- Trading Radar for 10/31: Chevron (CVX), NYSE Euronext (NYX), Cummins (CMI), Clorox (CL), Burger King (BKC) Report; Personal Income/Spending for Sept., UofM Sentiment Index Due
More News related to New Coverage
- Citi Initiates Coverage on US Soft Drink Makers
- William Blair Initiates Coverage on Data Networking Stocks
- Caris Starts Coverage on Ariba (ARBA), Concur (CNQR), salesforce.com (CRM), Taleo (TLEO)
- Oppenheimer Initiates Coverage on ViroPharma (VPHM)
- Oppenheimer Initiates Coverage on Cadence Pharmaceuticals (CADX) with an Outperform
Caris & Co initiates coverage on ev3 Inc. (Nasdaq: EVVV) with a Buy. Price target $14.
ev3 Inc. (ev3) is a global medical device company focused on catheter-based technologies for the endovascular treatment of vascular diseases and disorders.
Related Categories
New CoverageStocks Mentioned
-0.09Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
